Antibiotics or Placebo? The Effectiveness & Cost of Treating Children with Lower Respiratory Tract Infection

By Staff Writer

July 25, 2023

Antimicrobial drug resistance is a growing public health problem, particularly in relation to respiratory tract infections (RTIs) which are commonly treated in primary care. Antibiotic resistance is linked to primary care antibiotic prescribing and has significant cost implications. Despite a decrease in consultation and prescription rates for RTIs from the late 1990s to early 2000s, antibiotic use has fluctuated, rising again during the COVID-19 pandemic. Children have higher consultation rates for RTIs and are often prescribed antibiotics, even when these prescriptions are at their lowest. There is limited evidence to support the use of antibiotics for chest infections in children, and differences between adults and children mean adult-derived evidence cannot be directly applied. Both parents and clinicians have concerns about illness progression and potential adverse outcomes. The study aimed to assess the effectiveness of amoxicillin in children with uncomplicated lower respiratory tract infection.

 

A total of 432 children participated in this study- found that amoxicillin for uncomplicated lower respiratory tract infections in children is unlikely to be clinically effective or to reduce health or societal costs. The duration of symptoms was similar in the antibiotic and placebo groups, as were the rates of consultations, illness progression, and side effects. The costs per child to the NHS were slightly higher for antibiotics, but there was no difference in non-NHS costs. The study concluded that parents need better access to information and clear communication about managing their child’s illness. Clinicians also noted a reduction in parents’ expectations for antibiotics.

The study also found that the costs to the NHS per child were similar for both antibiotics and placebo (£29 vs £26), and societal costs were the same (£33). In the study they suggest that GPs should support parents to self-manage at home and provide clear communication about when and how to seek medical help. Parents whose children received antibiotics reported symptoms as moderately bad or worse for 5 days, while those given a placebo reported symptoms for 6 days. Side effects were similar in both groups. The study concluded that amoxicillin for chest infections in children is unlikely to be effective, and recommended that GPs support parents to self-manage at home while providing clear communication about when and how to seek medical help.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.